Daratumumab and venetoclax in combination with chemotherapy provide sustained molecular remission in relapsed/refractory CD19, CD20, and CD22 negative acute B lymphoblastic leukemia with KMT2A-AFF1 transcript
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2050-7771
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Daratumumab and venetoclax in combination with chemotherapy provide sustained molecular remission in relapsed/refractory CD19, CD20, and CD22 negative acute B lymphoblastic leukemia with KMT2A-AFF1 transcript ; volume:9 ; number:1 ; day:20 ; month:12 ; year:2021 ; pages:1-5 ; date:12.2021
Biomarker Research ; 9, Heft 1 (20.12.2021), 1-5, 12.2021
- Urheber
-
Voruz, Sophie
Blum, Sabine
de Leval, Laurence
Schoumans, Jacqueline
Solly, Françoise
Spertini, Olivier
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s40364-021-00343-3
- URN
-
urn:nbn:de:101:1-2022041420091055085715
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:37 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Voruz, Sophie
- Blum, Sabine
- de Leval, Laurence
- Schoumans, Jacqueline
- Solly, Françoise
- Spertini, Olivier
- SpringerLink (Online service)
Ähnliche Objekte (12)
Bcl2 inhibitor venetoclax +/− Anti-CD20: what do deep remissions mean?
Daratumumab Plus Carfilzomib: An Optimistic Approach in Relapsed/Refractory Multiple Myeloma
CD20 and CD19 targeted vectors induce minimal activation of resting B lymphocytes
CD19 and CD20 Targeted Vectors Induce Minimal Activation of Resting B Lymphocytes
Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma
Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX
Daratumumab
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
Venetoclax and Daratumumab combination treatment demonstrates pre-clinical efficacy in mouse models of Acute Myeloid Leukemia
Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy
Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial
Bcl2 inhibitor venetoclax +/− Anti-CD20: what do deep remissions mean?
Daratumumab Plus Carfilzomib: An Optimistic Approach in Relapsed/Refractory Multiple Myeloma
CD20 and CD19 targeted vectors induce minimal activation of resting B lymphocytes
CD19 and CD20 Targeted Vectors Induce Minimal Activation of Resting B Lymphocytes
Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma
Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX
Daratumumab
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
Venetoclax and Daratumumab combination treatment demonstrates pre-clinical efficacy in mouse models of Acute Myeloid Leukemia
Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy
Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial
Bcl2 inhibitor venetoclax +/− Anti-CD20: what do deep remissions mean?
Daratumumab Plus Carfilzomib: An Optimistic Approach in Relapsed/Refractory Multiple Myeloma
CD20 and CD19 targeted vectors induce minimal activation of resting B lymphocytes
CD19 and CD20 Targeted Vectors Induce Minimal Activation of Resting B Lymphocytes
Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma
Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX
Daratumumab
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
Venetoclax and Daratumumab combination treatment demonstrates pre-clinical efficacy in mouse models of Acute Myeloid Leukemia
Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy